K6-4fpCyto-13
ICGi021-A-1
General
Cell Line |
|
hPSCreg name | ICGi021-A-1 |
Cite as: | ICGi021-A-1 |
Alternative name(s) |
K6-4fpCyto-13
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
ICGi021-A-2 (K6-4fpCyto-16) ICGi021-A-3 (K6-4fpCyto-19) ICGi021-A (K6-4f) MRIi001-A-1 (C6-AAVS1-iCasRx) UCSFi001-A-12 (AICS-0036-006) CRMi003-A-3 (Proliving, GMNN-mScarletI Reporter) MRIi003-A-7 (HK-AAVS1-iCasRx) MRIi003-A-8 (HK-AAVS1-CAG-eGFP-homo) UCSFi001-A-23 (AICS-0054-091) UCSFi001-A-36 (AICS-0036-028) BIHi001-A-1 (iBCRT Cas9v1-3G-Kl.16) |
Last update | 12th July 2021 |
Notes | Healthy human iPSC clone with doxycycline-inducible expression of cytosolic Grx1-roGFP2 |
User feedback | |
Provider |
|
Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
Owner | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
External Databases |
|
BioSamples | SAMEA9000722 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Any
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Subclone of |
Donor Information
General Donor Information |
|
Sex | female |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
https://www.ncbi.nlm.nih.gov/sra/?term=SRR11413028 No disease associated mutation found |
External Databases (Donor) |
|
BioSamples | SAMEA6983569 |
Ethics
Also have a look at the ethics information for the parental line
ICGi021-A
.
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
The source cell information can be found in the parental cell line
ICGi021-A.
|
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Genes | |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Gelatin | ||||||||||||||||||
Feeder cells |
MEF cell Cellfinder Ont Id: http://www.ebi.ac.uk/efo/EFO_0004040 |
||||||||||||||||||
Passage method |
Enzymatically
TrypLE
|
||||||||||||||||||
O2 Concentration | 20 % | ||||||||||||||||||
CO2 Concentration | 5 % | ||||||||||||||||||
Medium |
Other medium:
Base medium: Knock-out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
Alkaline Phosphatase |
Yes |
Score:
Marker | Present | Absent |
mCpG | ||
OCT4 |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
Morphology
In vitro spontaneous differentiation
In vitro directed differentiation
Marker | Expressed |
aSMA |
Yes |
Collagen type I |
Yes |
Morphology
In vitro spontaneous differentiation
In vitro directed differentiation
Marker | Expressed |
Tubulin, beta 3 |
Yes |
Neurofilament 200 |
Yes |
Morphology
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Genetic Modification
Disease/phenotype related modifications |
|
Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.